Navigation Links
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selective VEGF signaling inhibitor - shows over a quarter of patients alive and progression- free at six months(1)

CHICAGO, June 04, 2007 /PRNewswire/ -- Data for the investigational agent cediranib (AZD2171) were presented today at the annual meeting of the American Society of Clinical Oncology (ASCO) from a study in patients with recurrent glioblastoma (GBM), an invasive form of brain tumor with a high unmet medical need. (1)

Cediranib Phase II monotherapy study in recurrent glioblastoma (GBM) Results from the National Cancer Institute (NCI) sponsored study at the Massachusetts General Hospital (MGH) Cancer Center, showed 8 patients (27.6%) of the 31 patients with recurrent glioblastoma treated with cediranib, were alive and progression-free at six months.(1) Recurrent glioblastoma is the most aggressive form of primary brain tumor. The dose limiting toxicities most commonly observed in this study included hypertension, fatigue, and diarrhea.

Cediranib is a selective VEGF signaling inhibitor that targets all three VEGF receptors.(2) VEGF signalling is a key driver of angiogenesis -- the formation of new blood vessels that tumors need to grow and spread. Cediranib is currently in Phase II/III development for advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer (CRC) -- as well as being investigated as part of a wide-ranging signal search program in other tumors such as glioblastoma.

Commenting on these results, Dr. Tracy Batchelor, MD, chief of Neuro- Oncology in the Massachusetts General Hospital (MGH) Cancer Center, Associate Professor of Neurology at Harvard Medical School and lead author of the Phase II study said, "These encouraging data showing effects on progression-free survival warrant further investigation to validate these initial trial results."

"In addition, cediranib alleviated brain swelling
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. ... inoperable solid tumor cancers, announced today that CEO Linda ... Phacilitate Immunotherapy Forum in Washington D.C. ... on January 26 at 10:30 a.m. EST at the Grand ...
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... Local Treatment of Oral Candidiasis in Immunosuppressed Patients in China ... 5 RHEI Pharmaceuticals, Inc. today announced that the final ... dose miconazole in a patented mucoadhesive system, has been initiated ... conducted for submission of the New Drug Application (NDA) to ...
... Orexigen(R) Therapeutics, Inc.,(Nasdaq: OREX ) today ... on its late-stage obesity programs and realign its,management team. ... aspects of these changes are as follows: , ... proof-of-concept Phase 2 trials for OREX-003,(zonisamide and olanzapine to ...
Cached Medicine Technology:RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... , WICHITA, Kan., Aug. 10 Operation Rescue ... aimed at stopping abortionist LeRoy Carhart from opening an international late-term ... considered an urgent priority in a larger c a ... in any state. , , In order for Carhart ...
... Chairman ... , ... (PRWEB) August 10, 2009 -- This year,s National Association of Chain Drug Stores ... focused extensively on the healthcare reform debate. During the 52nd annual Conference, experts ...
... , , NEW YORK, Aug. 10 ... leading global information and media company and the CLIO Awards, one of the ... the online entry system, currently open at www.CLIOHealthcare.com for first-ever CLIO ... has been extended. For all work appearing between January 1, 2008 and June ...
... , PITTSBURGH, Aug. 10 ... of diagnostic imaging professional services and Vital Images (Nasdaq: ... analysis software, have partnered to bring Vital Images, advanced visualization ... full suite of software exclusively with its customer base of ...
... idiopathic chronic cholestatic inflammatory liver disease characterized by diffuse ... in bile duct obliteration, biliary cirrhosis, and eventually hepatic ... time of presentation of PSC is mild to severe ... the mechanisms responsible for the abdominal pain in PSC ...
... or ,borrowed, drugs, study found , MONDAY, Aug. 10 (HealthDay ... drugs such as antibiotics and allergy medications with friends, a ... new study. , For example, a teen who,s taking the ... defects -- may give some to a friend who is ...
Cached Medicine News:Health News:Urgent Petition Launched to Block Plans for New International Late-Term Abortion Clinic 2Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 2Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 3Health News:NACDS Pharmacy and Technology Conference Focuses on Reform 4Health News:Nielsen Announces Entry Deadline Extension for the First-Ever CLIO Healthcare Awards 2Health News:Foundation Radiology Group and Vital Images' Partnership Brings Advanced Visualization to Small Medical Communities Nationwide 2Health News:Gallbladder emptying in primary sclerosing cholangitis patients 2Health News:Sharing Prescription Meds Common Among U.S. Teens 2
Agarose IEF is suitable for isoelectric focusing of large molecules and is the gel of choice for many IEF applications and immunochemical detection methods....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... purified non-ionic fraction of agar. Forms gel ... concentrations. Can be mounted on microscope slides ... elastic and durable and show little or ... or lipoprotein dyes. Contaminants: ash: ...
Medicine Products: